- Home
- FKWL vs CUE Comparison
FKWL vs CUE Comparison
Compare FKWL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FKWL
- CUE
- Stock Information
- Founded
- FKWL 1981
- CUE 2014
- Country
- FKWL United States
- CUE United States
- Employees
- FKWL N/A
- CUE N/A
- Industry
- FKWL Telecommunications Equipment
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- FKWL Utilities
- CUE Health Care
- Exchange
- FKWL Nasdaq
- CUE Nasdaq
- Market Cap
- FKWL 71.6M
- CUE 60.6M
- IPO Year
- FKWL 1996
- CUE 2018
- Fundamental
- Price
- FKWL $5.61
- CUE $0.91
- Analyst Decision
- FKWL
- CUE Strong Buy
- Analyst Count
- FKWL 0
- CUE 4
- Target Price
- FKWL N/A
- CUE $4.75
- AVG Volume (30 Days)
- FKWL 38.6K
- CUE 147.0K
- Earning Date
- FKWL 05-14-2025
- CUE 05-08-2025
- Dividend Yield
- FKWL N/A
- CUE N/A
- EPS Growth
- FKWL N/A
- CUE N/A
- EPS
- FKWL N/A
- CUE N/A
- Revenue
- FKWL $43,443,375.00
- CUE $9,532,000.00
- Revenue This Year
- FKWL N/A
- CUE $73.11
- Revenue Next Year
- FKWL N/A
- CUE $11.02
- P/E Ratio
- FKWL N/A
- CUE N/A
- Revenue Growth
- FKWL N/A
- CUE 149.53
- 52 Week Low
- FKWL $2.90
- CUE $0.45
- 52 Week High
- FKWL $7.45
- CUE $2.26
- Technical
- Relative Strength Index (RSI)
- FKWL 42.29
- CUE 32.51
- Support Level
- FKWL $5.12
- CUE $0.95
- Resistance Level
- FKWL $6.23
- CUE $1.05
- Average True Range (ATR)
- FKWL 0.42
- CUE 0.08
- MACD
- FKWL -0.06
- CUE 0.00
- Stochastic Oscillator
- FKWL 41.10
- CUE 19.62
About FKWL Franklin Wireless Corp.
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.